1-20 of 30
Thomas A. Waldmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors

Kevin Conlon, Rom Leidner, Douglas McNeel, Sumati Gupta, Andrea Wang-Gillam, Thomas A. Waldmann, George Pavlakis, Mirek Dostalek, Sema Kurtulus, Niladri Roy Chowdhury, Jessica O'Keeffe, Nehal S. Parikh, John A. Thompson
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT082.
https://doi.org/10.1158/1538-7445.AM2019-CT082
Published: 01 July 2019
View article titled, Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
Journal Articles

Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers

Geraldine OSullivan Coyne, Sabrina S. Khan, Kevin Conlon, Howard Streicher, Ashley Bruns, Richard Piekarz, Naoko Takebe, Lamin Juwara, Ralph Parchment, Tony Navas, Kirstin Fino, King L. Fung, Elad Sharon, James H. Doroshow, Thomas A. Waldmann, Alice P. Chen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-015.
https://doi.org/10.1158/1538-7445.AM2019-LB-015
Published: 01 July 2019
View article titled, Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers
Journal Articles

Abstract 1596: Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers

Kevin C. Conlon, Sigrid Dubois, Chyi-chia Richard Lee, Thomas Fleisher, Jennifer I. Hsu, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1596.
https://doi.org/10.1158/1538-7445.AM2017-1596
Published: 01 July 2017
View article titled, Abstract 1596: Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers
Journal Articles

IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy

Karolina Pilipow, Alessandra Roberto, Mario Roederer, Thomas A. Waldmann, Domenico Mavilio, Enrico Lugli
Journal: Cancer Research
Cancer Res (2015) 75 (24): 5187–5193.
https://doi.org/10.1158/0008-5472.CAN-15-1498
Published: 14 December 2015
View article titled, IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
Open the PDF for IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy in another window
Journal Articles

Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20

Bernard Wen, Meili Zhang, David Dilillo, Jeffrey V. Ravetch, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1332.
https://doi.org/10.1158/1538-7445.AM2015-1332
Published: 01 August 2015
View article titled, Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20
Journal Articles

Abstract 3936: Frequent gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATLL)

Masao Nakagawa, Roland Schmitz, Wenming Xiao, Carolyn K. Goldman, Weihong Xu, Yandan Yang, Xin Yu, Thomas A. Waldmann, Louis M. Staudt
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3936.
https://doi.org/10.1158/1538-7445.AM2015-3936
Published: 01 August 2015
View article titled, Abstract 3936: Frequent gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATLL)
Journal Articles

Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers

Kevin C. Conlon, Enrico Lugli, Steven A. Rosenberg, John C. Morris, Thomas Fleisher, Hugh Welles, Sigrid Dubois, Liyanage Perera, Carolyn Goldman, Bonita Bryant, Jean Decker, Joanna Shih, Tat'Yana Worthy, William Figg, Cody Peer, Michael Sneller, H. Clifford Lane, Jason Yovandich, Stephen Creekmore, Mario Roederer, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2575.
https://doi.org/10.1158/1538-7445.AM2014-2575
Published: 01 October 2014
View article titled, Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers
Journal Articles

Abstract 2526: CP690550 inhibits interleukin-2 (IL-2), IL-9 and IL-15 mediated JAK3 activation and proliferation of T cells obtained from patients with HTLV-1-associated adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Wei Ju, Meili Zhang, Bonita R. Bryant, Jing Chen, John C. Morris, John E. Janik, Thomas A. Waldmann, Jian-kang Jiang, Craig J. Thomas, Steven Jacobson, Unsong Oh
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 2526.
https://doi.org/10.1158/1538-7445.AM10-2526
Published: 15 April 2010
View article titled, Abstract 2526: CP690550 inhibits interleukin-2 (IL-2), IL-9 and IL-15 mediated JAK3 activation and proliferation of T cells obtained from patients with HTLV-1-associated adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Journal Articles

Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against the neu Oncogene through the Induction of Antibodies Partially Independent of CD4 Help

Jason C. Steel, Charmaine A. Ramlogan, Ping Yu, Yoshio Sakai, Guido Forni, Thomas A. Waldmann, John C. Morris
Journal: Cancer Research
Cancer Res (2010) 70 (3): 1072–1081.
https://doi.org/10.1158/0008-5472.CAN-09-1301
Published: 31 January 2010
View article titled, Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against the <em>neu</em> Oncogene through the Induction of Antibodies Partially Independent of CD4 Help
Open the PDF for Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against the <em>neu</em> Oncogene through the Induction of Antibodies Partially Independent of CD4 Help in another window
Journal Articles

The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the α-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia

Meili Zhang, Zhengsheng Yao, Zhuo Zhang, Kayhan Garmestani, Vladimir S. Talanov, Paul S. Plascjak, Sarah Yu, Hyung-Sik Kim, Carolyn K. Goldman, Chang H. Paik, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2006) 66 (16): 8227–8232.
https://doi.org/10.1158/0008-5472.CAN-06-1189
Published: 15 August 2006
View article titled, The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the α-Emitter <sup>211</sup>At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Open the PDF for The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the α-Emitter <sup>211</sup>At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia in another window
Journal Articles

Effective therapy of a murine model of anaplastic large cell lymphoma with an anti-CD30 monoclonal antibody, HeFi-1, armed with the alpha emitter, 211At.

Meili Zhang, Zhengsheng Yao, Hiral Patel, Zhuo Zhang, Kayhan Garmestani, Vladimir S. Talanov, Paul S. Plascjak, Carolyn K. Goldman, Martin W. Brechbiel, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1349–1350.
Published: 15 April 2006
View article titled, Effective therapy of a murine model of anaplastic large cell lymphoma with an anti-CD30 monoclonal antibody, HeFi-1, armed with the alpha emitter, <sup>211</sup>At.
Journal Articles

Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia

Meili Zhang, Zhuo Zhang, Kayhan Garmestani, Carolyn K. Goldman, Jeffrey V. Ravetch, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5825–5829.
https://doi.org/10.1158/0008-5472.CAN-04-1088
Published: 16 August 2004
View article titled, Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia
Open the PDF for Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia in another window
Journal Articles

Lymphatic drainage imaging of the breast cancer in mice using the micro-magnetic resonance mammo-lymphangiography using a nano-size contrast agent

Hisataka Kobayashi, Satomi Kawamoto, Yoshio Sakai, Peter L. Choyke, Martin W. Brechbiel, John C. Morris, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1305.
Published: 01 April 2004
View article titled, Lymphatic drainage imaging of the breast cancer in mice using the micro-magnetic resonance mammo-lymphangiography using a nano-size contrast agent
Journal Articles

Preclinical evaluation of an anti-CD25 monoclonal antibody armed with an alpha emitter, At-211, as a potential radioimmunotherapeutic agent for leukemia and lymphoma

Meili Zhang, Zhuo Zhang, Kayhan Garmestani, Hyung-Sik Kim, Carolyn K. Goldman, Chang Paik, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 956.
Published: 01 April 2004
View article titled, Preclinical evaluation of an anti-CD25 monoclonal antibody armed with an alpha emitter, At-211, as a potential radioimmunotherapeutic agent for leukemia and lymphoma
Journal Articles

Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity

Raya Mandler, Hisataka Kobayashi, Ella R. Hinson, Martin W. Brechbiel, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2004) 64 (4): 1460–1467.
https://doi.org/10.1158/0008-5472.CAN-03-2485
Published: 18 February 2004
View article titled, Herceptin-Geldanamycin Immunoconjugates: <subtitle>Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity</subtitle>
Open the PDF for Herceptin-Geldanamycin Immunoconjugates: <subtitle>Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity</subtitle> in another window
Journal Articles

Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H

Zhuo Zhang, Meili Zhang, Carolyn K. Goldman, Jeffrey V. Ravetch, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2003) 63 (19): 6453–6457.
Published: 14 October 2003
View article titled, Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H
Open the PDF for Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H in another window
Journal Articles

Micro-magnetic Resonance Lymphangiography in Mice Using a Novel Dendrimer-based Magnetic Resonance Imaging Contrast Agent

Hisataka Kobayashi, Satomi Kawamoto, Robert A. Star, Thomas A. Waldmann, Yutaka Tagaya, Martin W. Brechbiel
Journal: Cancer Research
Cancer Res (2003) 63 (2): 271–276.
Published: 15 January 2003
View article titled, Micro-magnetic Resonance Lymphangiography in Mice Using a Novel Dendrimer-based Magnetic Resonance Imaging Contrast Agent
Open the PDF for Micro-magnetic Resonance Lymphangiography in Mice Using a Novel Dendrimer-based Magnetic Resonance Imaging Contrast Agent in another window
Journal Articles

Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and 90Y-labeled 1,4,7,10-Tetraazacyclododecane- N,N′,N″,N‴ -tetraacetic Acid (DOTA)-Biotin

Zhengsheng Yao, Meili Zhang, Donald B. Axworthy, Karen J. Wong, Kayhan Garmestani, Luke Park, Chang W. Park, Robert W. Mallett, Louis J. Theodore, Eric K. Yau, Thomas A. Waldmann, Martin W. Brechbiel, Chang H. Paik, Ira Pastan, Jorge A. Carrasquillo
Journal: Cancer Research
Cancer Res (2002) 62 (20): 5755–5760.
Published: 15 October 2002
View article titled, Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and <sup>90</sup>Y-labeled 1,4,7,10-Tetraazacyclododecane- <em>N,N′,N″,N‴</em> -tetraacetic Acid (DOTA)-Biotin
Open the PDF for Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and <sup>90</sup>Y-labeled 1,4,7,10-Tetraazacyclododecane- <em>N,N′,N″,N‴</em> -tetraacetic Acid (DOTA)-Biotin in another window
Journal Articles

Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia

Chalet Tan, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2002) 62 (4): 1083–1086.
Published: 01 February 2002
View article titled, Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia
Open the PDF for Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia in another window
Journal Articles

IL-2Rα-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2Rα Interaction

Kathleen E. Phillips, Bert Herring, Latresia A. Wilson, Marc S. Rickford, Meili Zhang, Carolyn K. Goldman, J. Yun Tso, Thomas A. Waldmann
Journal: Cancer Research
Cancer Res (2000) 60 (24): 6977–6984.
Published: 01 December 2000
View article titled, IL-2Rα-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2Rα Interaction
Open the PDF for IL-2Rα-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2Rα Interaction in another window